-$0.66 Earnings Per Share Expected for Cellectis (CLLS) This Quarter

Brokerages expect that Cellectis (NASDAQ:CLLS) will post earnings of ($0.66) per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Cellectis’ earnings, with the highest EPS estimate coming in at ($0.59) and the lowest estimate coming in at ($0.71). Cellectis reported earnings of ($0.56) per share during the same quarter last year, which indicates a negative year over year growth rate of 17.9%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that Cellectis will report full-year earnings of ($2.62) per share for the current financial year, with EPS estimates ranging from ($2.69) to ($2.51). For the next year, analysts expect that the firm will report earnings of ($2.26) per share, with EPS estimates ranging from ($2.62) to ($1.72). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Cellectis.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.12). Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%. The firm had revenue of $6.91 million for the quarter, compared to analyst estimates of $10.10 million.

Several equities research analysts recently weighed in on CLLS shares. Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a report on Thursday, December 28th. BidaskClub downgraded Cellectis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 16th. Nomura raised their price objective on Cellectis to $73.00 and gave the company a “buy” rating in a report on Wednesday, March 14th. Guggenheim started coverage on Cellectis in a report on Friday, March 16th. They set a “neutral” rating on the stock. Finally, ValuEngine raised Cellectis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $42.67.

Shares of NASDAQ CLLS traded down $0.82 during mid-day trading on Friday, hitting $30.05. 186,222 shares of the stock traded hands, compared to its average volume of 309,767. Cellectis has a twelve month low of $21.25 and a twelve month high of $38.85. The company has a market cap of $1,285.19, a price-to-earnings ratio of -10.96 and a beta of 1.86.

A number of large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in Cellectis during the 4th quarter worth $10,203,000. BlackRock Inc. bought a new position in Cellectis during the 4th quarter worth $4,422,000. Millennium Management LLC raised its position in Cellectis by 1,356.2% during the 4th quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock worth $3,040,000 after purchasing an additional 97,128 shares during the last quarter. Bain Capital Public Equity Management LLC bought a new position in Cellectis during the 4th quarter worth $2,848,000. Finally, Granite Point Capital Management L.P. bought a new position in Cellectis during the 4th quarter worth $1,458,000. 20.30% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.chaffeybreeze.com/2018/04/19/0-66-earnings-per-share-expected-for-cellectis-clls-this-quarter.html.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply